Avastin/FOLFIRI in Combination With Curcumin in Colorectal Cancer Patients With Unresectable Metastasis

Phase 2 Completed 44 enrolled Gachon University Gil Medical Center Aju Pharm · collab

NaSingle-groupOpen-labelTreatment

Summary

Oral curcumin-containing supplement will be given to colorectal cancer patients with unresectable metastases who will be starting Avastin/FOLFIRI chemotherapy for up to completion of (or withdrawal from) chemotherapy.

Timeline

Start: 2015-08-24
Primary completion: 2019-08-01
Completion: 2019-08-01

Publications

Jeon Y, Sym SJ, Yoo BK, Baek JH. Long-term Survival, Tolerability, and Safety of First-Line Bevacizumab and FOLFIRI in Combination With Ginsenoside-Modified Nanostructured Lipid Carrier Containing Curcumin in Patients With Unresectable Metastatic Colorectal Cancer. Integr Cancer Ther. 2022 Jan-Dec;21:15347354221105498. doi: 10.1177/15347354221105498.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Curcumin	Small molecule	100 mg	Oral
Background	Bevacizumab	Monoclonal antibody	5 mg/kg	Intravenous
Background	Irinotecan	Small molecule	180 mg/m2	Intravenous
Background	Leucovorin	Small molecule	200 mg/m2	Intravenous
Background	fluorouracil	Small molecule	400 mg/m2	Intravenous
Background	fluorouracil	Small molecule	1200 mg/m2	Intravenous

Avastin/FOLFIRI in Combination With Curcumin in Colorectal Cancer Patients With Unresectable Metastasis

Summary

Timeline

Publications

Drugs

Indications